医療機器リーダーシリーズ:体外診断用医療機器(IVD)の上位企業2017-2027

◆英語タイトル:Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027-Leading IVD Companies in the US, Europe and Asia
◆商品コード:VGAIN61207
◆発行会社(調査会社):visiongain
◆発行日:2016年11月
◆ページ数:185
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥297,851見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥446,851見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥744,851見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain’s new report Medical Devices Leader Series – Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia shows you the prospects of leading IVD companies to 2027.

Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027.

Our report forecasts to 2027 the overarching IVD market and its main segments:
• Point-of-care (POC) tests
• Clinical chemistry
• Immunochemistry
• Haematological diagnostics
• Microbiological applications
• Genetic testing agents
• Other products

This report provides profiles, discussions and financial analyses – including revenue forecasts to 2027 – for top US IVD companies:
• Danaher
• Abbott Laboratories
• Johnson & Johnson (J&J)
• Bio-Rad
• Becton Dickinson
• Thermo Fisher Scientific

Our report shows you developments and revenue forecasts to 2027 for leading diagnostics companies based in Europe:
• Roche
• Siemens
• bioMérieux

This report also provides outlooks and revenue forecasts to 2027 for top Japanese companies developing and producing IVD tests:
• Sysmex
• Arkray

Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations:
• Dako (Agilent Technologies)
• Genomic Health
• Laboratory Corporation of America (LabCorp)
• MDxHealth
• Myriad Genetics
• QIAGEN

Our 185 page report provides 65 tables and 75 figures covering 7 different IVD submarkets, leading companies in the US, Europe and Asia.

Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.

【レポートの目次】

1. Report Overview
1.1 How This Report Delivers Information
1.2 Main Questions This Report Answers
1.3 Who is This Report For?
1.4 Methods of Research and Analysis
1.5 Frequently Asked Questions (FAQs)
1.6 Some Related Reports
1.7 About Visiongain

2. An Introduction to In Vitro Diagnostics
2.1 The In Vitro Diagnostics Market
2.1.1 The In Vitro Diagnostics Market in 2017
2.2 What are In Vitro Diagnostic (IVD) Tests?
2.3 Classifying In Vitro Diagnostics
2.3.1 The US Classification
2.3.2 The EC (European Commission) Classification
2.3.3 Regulatory Issues in the IVD Market
2.3.3.1 Regulation of IVD Tests
2.3.3.2 Lack of Clarity Can be Costly
2.4 Types of IVD Test
2.4.1 Point of Care Diagnostics
2.4.2 Clinical Chemistry
2.4.3 Microbiology
2.4.3.1 Regulatory Differences with IVD Microbiology Tests
2.4.4 Haematology
2.4.5 Immunochemistry
2.4.6 Genetic Testing
2.5 The IVD Market: Overall Revenue Forecast to 2027
2.5.1 Market Drivers, 2016-2027
2.5.2 Market Restraints, 2016-2027
2.5.3 Future of the IVD Industry
2.6 Company Comparison
2.6.1 Fragmented Market
2.6.2 IVD Market: Leading Manufacturers in 2016

3. The Leading US In Vitro Diagnostic Companies, 2016-2027
3.1 Danaher
3.1.1 Sales and Recent Performance Analysis
3.1.2 Life Sciences and Diagnostics
3.1.3 Key Products
3.1.4 Danaher Manufacturing Capabilities
3.1.5 Danaher IVD Segment: Strengths and Challenges
3.1.6 Danaher’s Life Sciences and Diagnostics Revenues
3.1.6.1 IVD Revenue Forecast, 2016-2027
3.1.7 Recent Mergers and Acquisition (M&A) Activity
3.2 Abbott Laboratories
3.2.1 Sales and Recent Performance Analysis
3.2.2 Abbott: Diagnostics Segment
3.2.2.1 In Vitro Diagnostics Products
3.2.3 Abbott IVD Segment: Strengths and Challenges
3.2.4 Abbott Diagnostics Historical Revenues, 2013-2015
3.2.5 IVD Revenue Forecast, 2016-2027
3.2.6 Recent M&A Activity and Strategic Collaborations
3.2.6.1 Collaboration with GSK
3.2.6.2 Collaboration with Merck
3.2.6.3 Acquisition of STARLIMS Technologies
3.2.6.4 Acquisition of Ibis Biosciences, Inc.
3.2.7 Plans to Separate into Two Publicly Traded Companies
3.3 Johnson & Johnson (J&J)
3.4 Bio-Rad
3.4.1 Sales and Recent Performance Analysis
3.4.2 Clinical Diagnostics
3.4.2.1 In Vitro Diagnostics
3.4.3 IVD Revenue 2015
3.4.4 IVD Revenue Forecast, 2017-2026
3.4.5 Recent M&A Activity and Strategic Collaborations
3.4.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
3.5 Becton Dickinson
3.5.1 Global Presence
3.5.2 Distribution
3.5.3 R&D
3.5.4 Sales and Recent Performance Analysis
3.5.4.1 Historical Sales Performance Analysis
3.5.5 BD Diagnostics Revenue
3.5.6 IVD Revenue Forecast, 2017-2027
3.5.7 Recent M&A Activity and Strategic Collaborations
3.6 Thermo Fisher Scientific
3.6.1 Historical Sales and Recent Performance Analysis
3.6.2 Clinical Diagnostics
3.6.3 Key Products
3.6.4 Thermo Fisher’s Manufacturing Capabilities
3.6.5 Thermo Fisher’s Diagnostics Revenues
3.6.6 IVD Revenue Forecast 2016-2027
3.6.7 Recent Mergers and Acquisition Activity
3.6.7.1 Acquisition of Dionex and Phadia

4. The Leading European In Vitro Diagnostic Companies, 2016-2027
4.1 Roche
4.1.1 Global Presence
4.1.2 Sales and Recent Performance Analysis
4.1.3 Roche Diagnostics
4.1.4 R&D Capabilities
4.1.5 Growing Portfolio of Diagnostic Products
4.1.5.1 Exploring Strategies in the Neurological Sector
4.1.6 IVD Revenue Forecast 2016-2027
4.1.7 Recent M&A Activity and Strategic Collaborations
4.1.7.1 Roche Offers to Acquire Illumina to Strengthen its Leading Position in Diagnostics
4.2 Siemens
4.2.1 Sales and Recent Performance, 2015
4.2.2 Siemens Healthcare
4.2.2.1 Siemens Diagnostics
4.2.2.2 Outperforming the Market
4.2.2.3 In Vitro Diagnostics
4.2.3 IVD Revenue Forecast 2016-2027
4.2.4 Recent M&A Activity and Strategic Collaborations
4.2.4.1 Partnership with ViiV Healthcare
4.2.4.2 Partnership with Tocagen
4.3 bioMérieux
4.3.1 Sales and Recent Performance, 2015
4.3.2 IVD Revenue Forecast 2016-2027
4.3.3 Recent M&A Activity and Strategic Collaborations
4.3.3.1 Partnership with GSK
4.3.3.2 Partnership with Ipsen
4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
4.3.3.4 Collaboration with Hospices Civils de Lyon
4.3.3.5 Acquisition of ARGENE
4.3.3.6 Equity Interest in Knome

5. The Leading Japanese In Vitro Diagnostic Companies, 2016-2027
5.1 Sysmex
5.1.1 Global Presence and Distribution
5.1.2 Sales and Recent Performance Analysis
5.1.3 Sysmex Diagnostics
5.1.4 IVD Revenue Forecast 2016-2027
5.1.5 Recent M&A Activity and Strategic Collaborations
5.1.5.1 Acquisition of Katakura’s Research Institute of Biological Science
5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
5.2 Arkray
5.2.1 Global Presence
5.2.2 R&D
5.2.3 IVD Product Portfolio
5.2.4 Sales and Recent Performance Analysis
5.2.5 IVD Revenue Forecast 2016-2027

6. Emerging In Vitro Diagnostic Companies, 2017
6.1 Pipeline and Other Companies: An Overview, 2017
6.2 Other Prominent In Vitro Diagnostic Players
6.3 Dako (Agilent Technologies)
6.3.1 Sales and Recent Performance Analysis
6.3.2 M&A Activity and Other Key Developments
6.4 Genomic Health
6.4.1 Sales and Recent Performance Analysis
6.4.2 R&D Capabilities
6.4.2.1 TAILORx Clinical Trial
6.4.2.2 RxPonder Trial
6.4.2.3 Partnership with Oncomed
6.5 Laboratory Corporation of America (LabCorp)
6.5.1 Sales and Recent Performance Analysis
6.5.2 In Vitro Diagnostics
6.6 Recent M&A Activity and Other Key Developments
6.6.1 Agreement with Medco Health Sciences
6.6.2 Acquisition of Monogram Biosciences
6.6.3 Non-Exclusive License Agreement with Merck
6.6.4 Acquisition of Genzyme Genetics
6.6.5 Partnership with ARCA Biopharma
6.7 MDxHealth
6.7.1 Sales and Recent Performance Analysis, 2015
6.7.2 R&D Capabilities
6.7.3 In Vitro Diagnostics
6.7.3.1 PharmacoMDx
6.7.3.2 PredictMDx for Brain Cancer
6.7.3.3 PredictMDx for Colon Cancer
6.7.3.4 Partnership with GSK
6.8 Myriad Genetics
6.8.1 Sales and Recent Performance Analysis
6.8.2 R&D Capabilities
6.8.3 In Vitro Diagnostics
6.8.3.1 Myriad RBM
6.8.4 M&A Activity and Recent Partnerships
6.8.4.1 Agreement with BioMarin Pharmaceutical
6.8.4.2 Acquisition of Myriad RBM
6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
6.8.4.4 Agreement with Cephalon
6.8.4.5 Agreement with PharmaMar
6.9 QIAGEN
6.9.1 Sales and Recent Performance Analysis
6.9.2 Continued Expansion in the Emerging Markets
6.9.3 R&D Capabilities
6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
6.9.4 Recent M&A Activity and Other Developments
6.9.4.1 Acquisition of Cellestis Ltd.
6.9.4.2 Acquisition of Ipsogen
6.9.4.3 Partnership with Pfizer
6.9.4.4 Partnership with Eli Lilly
6.9.4.5 Acquisition of SABiosciences Corporation
6.9.4.6 Acquisition of DxS Ltd (Now QIAGEN Manchester)
6.9.4.7 Acquisition of Explera s.r.l

7. Conclusions
7.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market
7.2 Big Pharma Dominated the IVD Market in 2015
7.3 The Rise of ‘Generic Medical Devices’
7.4 What Will Succeed in the IVD Market?
7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2027

Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form



Table of Figures
Figure 2.1 IVD Market ($bn) by Class 2017
Figure 2.2 IVD: Overall Market ($bn) Forecast , 2016, 2017, 2021 & 2027
Figure 2.3 IVD Market: Drivers and Restraints, 2016-2027
Figure 2.4 Leading Companies in the IVD Market: Net Sales ($bn), 2016
Figure 2.5 Leading Companies in the IVD Industry: Market Shares (%), 2016
Figure 3.1 Danaher: Net Sales ($bn) by Business Segment, 2015
Figure 3.2 Danaher: Revenue Shares (%) by Business Segment, 2015
Figure 3.3 Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 3.4 Danaher: IVD Market Share (%), 2016-2027
Figure 3.5 Abbott: Net Sales ($bn) by Business Segment, 2015
Figure 3.6 Abbott: Revenue Shares (%) by Business Segment, 2015
Figure 3.7 Abbott IVD Historical Performance 2012-2015: Revenue ($bn), AGR (%)
Figure 3.8 Abbott: Revenues ($bn) by Region, 2015
Figure 3.9 Abbott: Revenue Shares (%) by Region, 2015
Figure 3.10 Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 3.11 Abbott: IVD Market Share (%), 2016-2027
Figure 3.12 Bio-Rad: Historical Diagnostics Revenues ($bn), AGR (%), 2013-2015
Figure 3.13 Bio-Rad: Revenue Shares (%) by Business Segment, 2015
Figure 3.14 Bio-Rad: Revenue Shares (%) by Region, 2015
Figure 3.15 Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2016-2027
Figure 3.16 Bio-Rad: IVD Market Share (%), 2016-2027
Figure 3.17 BD: Company Revenue ($bn), 2013-2015
Figure 3.18 BD IVD Revenue Forecast ($bn), AGR (%), 2016-2027
Figure 3.19 BD: IVD Market Share (%), 2016-2027
Figure 3.20 Thermo Fisher: IVD Net Sales ($bn), 2013-2015
Figure 3.21 Thermo Fisher: Revenue Shares (%) by Sector, 2015
Figure 3.22 Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 3.23 Thermo Fisher: IVD Market Share (%), 2016-2027
Figure 3.24 Thermo Fisher: Mergers & Acquisitions
Figure 4.1 Roche: Revenues ($bn) by Sector, 2015
Figure 4.2 Roche: Revenue Shares (%) by Sector, 2015
Figure 4.3 Roche Diagnostics: Revenue Shares (%) by Region, 2015
Figure 4.4 Roche Diagnostics: Revenues ($bn) by Sector, 2015
Figure 4.5 Roche Diagnostics: Revenue Shares (%) by Sector, 2015
Figure 4.6 Roche: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027
Figure 4.7 Roche: IVD Market Share (%), 2016-2027
Figure 4.8 Siemens: Revenue Shares (%) by Sector, 2015
Figure 4.9 Siemens Healthcare: Revenue Shares (%) by Region, 2015
Figure 4.10 Siemens: IVD Revenue ($bn), AGR (%), Forecast 2016-2027
Figure 4.11 Siemens: IVD Market Share (%), 2015-2027
Figure 4.12 bioMérieux: Revenue ($bn) by Sector, 2015
Figure 4.13 bioMérieux: Revenue Shares (%) by Sector, 2015
Figure 4.14 bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2015
Figure 4.15 bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2015
Figure 4.16 bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027
Figure 4.17 bioMérieux: IVD Market Share (%), 2016-2027
Figure 5.1 Sysmex: Revenues ($m) by Sector, 2015
Figure 5.2 Sysmex: Revenue Shares (%) by Sector, 2015
Figure 5.3 Sysmex: Net Sales (%) by Geographical Region, 2015
Figure 5.4 Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 5.5 Sysmex: IVD Market Share (%), 2016-2027
Figure 5.6 Arkray: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 5.7 Arkray: IVD Market Share (%), 2015-2027
Figure 6.1 Aglient: Revenue ($bn) by Sector, 2015
Figure 6.2 Dako: Revenue Shares (%) by Sector, 2015
Figure 6.3 Genomic Health: Historical Revenues ($m) and Net Income ($m), 2011-2015
Figure 6.4 Genomic Health: Revenue Shares (%) by Reporting Segment, 2015
Figure 6.5 Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2011-2015
Figure 6.6 LabCorp: Historical Revenue ($bn), Profit ($bn), 2011-2015
Figure 6.7 LabCorp: Revenues ($bn) by Reporting Segment, 2015
Figure 6.8 LabCorp: Revenue Shares (%) by Reporting Segment, 2015
Figure 6.9 MDxHealth: Revenues ($m) by Reporting Segment, 2016
Figure 6.10 MDxHealth: Revenue Shares (%) by Reporting Segment, 2015
Figure 6.11 Myriad: Historical Net Revenues ($m), 2012-2016
Figure 6.12 Myriad: Revenue Shares (%) by Sector, 2016
Figure 6.13 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2016
Figure 6.14 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2016
Figure 6.15 Myriad: Historical R&D Investments ($m), 2012-2016
Figure 6.16 QIAGEN: Historical Revenue ($m), Net Income ($m), 2011-2015
Figure 6.16 QIAGEN: Revenues ($m) by Customer Class, 2015
Figure 6.17 QIAGEN: Revenue Shares (%) by Customer Class, 2015
Figure 6.18 QIAGEN: Revenue Shares (%) by Region, 2015
Figure 6.19 QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2015
Figure 7.1 IVD Market: Overall World Revenue ($bn), (AGR%) 2016-2027
Figure 7.2 Leading Market Segment: Revenue ($bn) Forecasts, 2016-2027

【レポートのキーワード】

体外診断用医療機器(IVD)

★調査レポート[医療機器リーダーシリーズ:体外診断用医療機器(IVD)の上位企業2017-2027] (コード:VGAIN61207)販売に関する免責事項を必ずご確認ください。
★調査レポート[医療機器リーダーシリーズ:体外診断用医療機器(IVD)の上位企業2017-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆